Two Stanford grads raise $11M to build a noninvasive wearable for hormone tracking

Clair Health announced a $11 million seed funding round on May 21, 2024, to develop a noninvasive wearable device for hormone tracking. The device, priced at $369, will be complemented by a $9.99 monthly app-based subscription. This funding aims to bring their technology to market, offering individuals a new way to monitor their hormonal health without invasive procedures. The company was founded by two Stanford University graduates. The wearable is designed to provide continuous, real-time data on hormone levels, which can be crucial for managing conditions like PCOS, infertility, and menopause, or for general wellness tracking. Clair Health plans to use the investment to scale its manufacturing, expand its research and development team, and initiate clinical trials to validate the accuracy and efficacy of its device. The goal is to empower users with actionable insights into their bodies' internal states, facilitating more informed health decisions and personalized treatment plans. The company anticipates a phased product launch, beginning with early adopters and expanding to the broader consumer market within the next two years.